Abstract
With the increasing prevalence of marijuana use in the US, many deceased organ donors have a history of marijuana use, raising concerns about infectious risks to transplant recipients. We performed a multicenter retrospective cohort study in which exposed donors were those with recent marijuana use (in the prior 12 months) and unexposed donors were those with no recent marijuana use. Primary outcomes included the following: (1) positive donor cultures for bacteria or fungi, (2) recipient infection due to bacteria or fungi within 3 months posttransplant, and (3) recipient graft failure or death within 12 months posttransplant. Multivariable regression was used to evaluate the relationship between donor marijuana use and each outcome. A total of 658 recipients who received organs from 394 donors were included. Recent marijuana use was not associated with donor culture positivity (aOR: 0.84, 95% CI: 0.39-1.81, P = .65), recipient infection (aHR: 1.02, 95% CI: 0.76-1.38, P = .90), or recipient graft failure or death (aHR: 1.65, 95% CI: 0.90-3.02, P = .11). Our data suggest that organs from donors with a history of recent marijuana use do not pose significant infectious risks in the early posttransplant period.
Keywords: donor selection, donor substance use, donor-derived infection, transplant infectious disease
Copyright © 2024 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Emily Blumberg receives research support from Merck, Takeda, Hologic, and Scynexis; was a member of a Data and Safety Monitoring Board (DSMB) for Amplyx; and is a member of Scientific Advisory Committees for Merck and Takeda. Jennifer Han was affiliated with the University of Pennsylvania during the conduct of this research and is now employed by, and holds shares in, the GlaxoSmithKline group of companies. Ebbing Lautenbach is a member of a DSMB for Merck and is a member of a scientific advisory committee for Paratek and Shionogi. None of these conflicts are relevant to this article. All other authors report no disclosures.
Similar articles
-
Impact of deceased organ donor injection drug use on donor culture positivity and recipient outcomes.Transpl Infect Dis. 2022 Dec;24(6):e13942. doi: 10.1111/tid.13942. Epub 2022 Aug 30.PMID: 35986571 Free PMC article.
-
Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes.Transpl Infect Dis. 2022 Feb;24(1):e13783. doi: 10.1111/tid.13783. Epub 2022 Jan 10.PMID: 34968006 Free PMC article.
-
Patterns in Use and Transplant Outcomes Among Adult Recipients of Kidneys From Deceased Donors With COVID-19.JAMA Netw Open. 2023 May 1;6(5):e2315908. doi: 10.1001/jamanetworkopen.2023.15908.PMID: 37252739 Free PMC article.
-
Bronchial Culture Growth From the Donor and Recipient as Predictive Factors in the Detection of Primary Graft Dysfunction and Pneumonia After Lung Transplant.Exp Clin Transplant. 2022 Oct;20(10):930-936. doi: 10.6002/ect.2021.0496. Epub 2022 May 23.PMID: 35607803
-
Utility of deceased donor cultures in solid organ transplantation in preventing donor-derived bacterial and fungal infectious diseases transmission.Transpl Infect Dis. 2023 Apr;25(2):e14032. doi: 10.1111/tid.14032. Epub 2023 Feb 7.PMID: 36748658 Review.